Please enable JavaScript
Powered by Benchmark International Archives - Page 408 of 1774 - Matribhumi Samachar English
Monday, December 29 2025 | 12:01:46 PM
Home / International (page 408)

International

TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel

Vancouver, British Columbia–(Newsfile Corp. – October 10, 2025) – TempraMed Technologies Ltd. (the “Company“) is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the “Prospectus“), with the British Columbia Securities Commission and …

Read More »

Scandium International Mining Announces Grant of New Mining Lease at Nyngan Scandium Project

Reno, Nevada–(Newsfile Corp. – October 10, 2025) – Scandium International Mining Corp. (TSXV: SCY) (OTC Pink: SCYYF) (“Scandium International” or the “Company“) is pleased to announce that the Department of Primary Industrials and Regional Development – NSW Resources (“the Department“) has granted a mining license to Scandium International’s wholly-owned subsidiary, …

Read More »

St. Augustine Gold and Copper Limited Advances Kingking Project to Definitive Feasibility Study and Engages Consulting Engineering Firms

Manila, Philippines–(Newsfile Corp. – October 10, 2025) –  St. Augustine Gold and Copper Limited (TSX: SAU) (“St. Augustine” or the “Company”) is pleased to announce the engagement of Stantec Consulting Ltd. (“Stantec”) and Independent Mining Consultants, Inc. (“IMC”) to complete a Definitive Feasibility Study (DFS) for the Kingking Copper-Gold Project …

Read More »

StrategX Issues Shares in Settlement of Debt

Vancouver, British Columbia–(Newsfile Corp. – October 10, 2025) – StrategX Elements Corp. (CSE: STGX) (“StrategX” or the “Company“) announces that further to its news release of October 3, 2025, it has now issued an aggregate of 2,342,304 common shares at a deemed price of $0.18 per share to settle aggregate …

Read More »

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival New York, New York–(Newsfile Corp. – October 10, 2025) – OS Therapies Inc. (NYSE American: …

Read More »